Genetic markers for the diagnosis and prognosis of pheochromocytoma

References

• Dahia PL, Ross KN, Wright ME et al. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet.1(1), 72–80 (2005).
   PubMedGoogle Scholar
• Eisenhofer G, Huynh TT, Pacak K et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel–Lindau syndrome. Endocr. Relat. Cancer11(4), 897–911 (2004).
   PubMedGoogle Scholar
• Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab.90(4), 2110–2116 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein RE, O’Neill JA Jr, Holcomb GW 3rd et al. Clinical experience over 48 years with pheochromocytoma. Ann. Surg.229(6), 755–764 (1999).
   Google Scholar
• Edstrom Elder E, Hjelm Skog AL, Hoog A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur. J. Surg. Oncol.29(3), 278–283 (2003).
   Google Scholar
• Gimenez-Roqueplo AP, Favier J, Rustin P et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res.63(17), 5615–5621 (2003).
   PubMed Web of Science ®Google Scholar
• Gao B, Meng F, Bian W et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology68(2), 282–286 (2006).
   Google Scholar
• Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol.26(5), 551–566 (2002).
   PubMed Web of Science ®Google Scholar
• Strong VE, Kennedy T, Al-Ahmadie H et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery143(6), 759–768 (2008).
   Google Scholar
• Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol.23(34), 8812–8818 (2005).
   PubMed Web of Science ®Google Scholar
• Favier J, Kempf H, Corvol P, Gasc JM. Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase. FEBS Lett.462(1–2), 19–24 (1999).
   PubMed Web of Science ®Google Scholar
• Ballester R, Marchuk D, Boguski M et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell63(4), 851–859 (1990).
   PubMed Web of Science ®Google Scholar
• Califano D, Rizzo C, D’Alessio A et al. Signaling through Ras is essential for RET oncogene-induced cell differentiation in PC12 cells. J. Biol. Chem.275(25), 19297–19305 (2000).
   Google Scholar
• Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell8(2), 155–167 (2005).
   PubMed Web of Science ®Google Scholar
• Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience147(4), 928–937 (2007).
   Google Scholar
• Powers JF, Tischler AS, Mohammed M, Naeem R. Microarray-based comparative genomic hybridization of pheochromocytoma cell lines from neurofibromatosis knockout mice reveals genetic alterations similar to those in human pheochromocytomas. Cancer Genet. Cytogenet.159(1), 27–31 (2005).
   Google Scholar
• Dahia PL. Evolving concepts in pheochromocytoma and paraganglioma. Curr. Opin. Oncol.18(1), 1–8 (2006).
   Google Scholar
• Dahia PL, Hao K, Rogus J et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res.65(21), 9651–9658 (2005).
   PubMed Web of Science ®Google Scholar
• August C, August K, Schroeder S et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod. Pathol.17(9), 1119–1128 (2004).
   Google Scholar
• Cascon A, Ruiz-Llorente S, Rodriguez-Perales S et al. A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma. Genes Chromosomes Cancer42(3), 260–268 (2005).
   Google Scholar
• Dannenberg H, Speel EJ, Zhao J et al. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am. J. Pathol.157(2), 353–359 (2000).
   Google Scholar
• Edstrom E, Mahlamaki E, Nord B et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am. J. Pathol.156(2), 651–659 (2000).
   Google Scholar
• Jarbo C, Buckley PG, Piotrowski A et al. Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. Int. J. Cancer118(5), 1159–1164 (2006).
   Google Scholar
• Aarts M, Dannenberg H, deLeeuw RJ et al. Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1–0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer45(1), 83–93 (2006).
   Google Scholar
• Brouwers FM, Eisenhofer G, Tao JJ et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J. Clin. Endocrinol. Metab.91(11), 4505–4509 (2006).
   PubMed Web of Science ®Google Scholar
• Rao F, Keiser HR, O’Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension36(6), 1045–1052 (2000).
   Google Scholar
• Proye C, Fossati P, Fontaine P et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery100(6), 1154–1162 (1986).
   PubMedGoogle Scholar
• Eisenhofer G, Goldstein DS, Sullivan P et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J. Clin. Endocrinol. Metab.90(4), 2068–2075 (2005).
   PubMed Web of Science ®Google Scholar
• John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology53(4), 679–683 (1999).
   PubMed Web of Science ®Google Scholar
• Thouennon E, Elkahloun AG, Guillemot J et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J. Clin. Endocrinol. Metab.92(12), 4865–4872 (2007).
   PubMedGoogle Scholar
• Yon L, Guillemot J, Montero-Hadjadje M et al. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J. Clin. Endocrinol. Metab.88(6), 2579–2585 (2003).
   PubMedGoogle Scholar
• Guillemot J, Barbier L, Thouennon E et al. Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas. Ann. NY Acad. Sci.1073, 527–532 (2006).
   Google Scholar
• Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am. J. Pathol.161(4), 1235–1246 (2002).
   PubMed Web of Science ®Google Scholar
• Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS111(4), 458–464 (2003).
   PubMed Web of Science ®Google Scholar
• Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab.86(11), 5615–5619 (2001).
   Google Scholar
• Boltze C, Mundschenk J, Unger N et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J. Clin. Endocrinol. Metab.88(9), 4280–4286 (2003).
   Google Scholar
• Khorram-Manesh A, Ahlman H, Jansson S, Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr. Pathol.13(2), 99–110 (2002).
   PubMed Web of Science ®Google Scholar
• Salmenkivi K, Arola J, Voutilainen R et al. Inhibin/activin β-subunit expression in pheochromocytomas favors benign diagnosis. J. Clin. Endocrinol. Metab.86(5), 2231–2235 (2001).
   Web of Science ®Google Scholar
• Ohta S, Lai EW, Pang AL et al. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int. J. Cancer114(1), 139–143 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta D, Shidham V, Holden J, Layfield L. Prognostic value of immunohistochemical expression of topoisomerase-α II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl. Immunohistochem. Mol. Morphol.8(4), 267–274 (2000).
   Google Scholar
• Salmenkivi K, Heikkila P, Haglund C, Louhimo J, Arola J. Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas. Histopathology43(1), 62–71 (2003).
   Google Scholar
• Petri BJ, Speel EJ, Korpershoek E et al. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Mod. Pathol.21(4), 407–413 (2008).
   Google Scholar
• Benn DE, Gimenez-Roqueplo AP, Reilly JR et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab.91(3), 827–836 (2006).
   PubMed Web of Science ®Google Scholar
• Amar L, Baudin E, Burnichon N et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab.92(10), 3822–3828 (2007).
   Google Scholar
• Neumann HP, Pawlu C, Peczkowska M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA292(8), 943–951 (2004).
   PubMed Web of Science ®Google Scholar
• Brouwers FM, Elkahloun AG, Munson PJ et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann. NY Acad. Sci.1073, 541–556 (2006).
   Google Scholar
• Anouar Y, Yon L, Guillemot J et al. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches. Ann. NY Acad. Sci.1073, 533–540 (2006).
   Google Scholar
• Fränkel F. Ein Fall von doppelseitigem, völlig latent verlaufenen nebennierentumor und gleichzeitiger nephritis mit veränderungen am circulationsapparat und retinitis. Arch. Pathol. Anat. Physiol. Klin. Med.103, 244–263 (1886).
   Google Scholar